COMPOSITIONS COMPRISING BACTERIAL STRAINS
The invention provides a composition comprising a bacterial strain of the genus Megasphaera , for use in the treatment or prevention of an autoimmune or inflammatory disorder or cancer
1 - 19 . (canceled)
20 . A method for treating or preventing a disease or condition mediated by Class I HDAC activity in a subject in need thereof, comprising administering to the subject in need thereof a bacterial strain having a 16S rRNA gene sequence with at least 97% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 14, 15, 16, 17 and 18.
21 . The method of claim 20 , wherein the identity is determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2.
22 . The method of claim 20 , wherein the 16S rRNA gene sequence has at least 98% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 14, 15, 16, 17 and 18.
23 . The method of claim 22 , wherein the 16S rRNA gene sequence has at least 99% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 14, 15, 16, 17 and 18.
24 . The method of claim 22 , wherein the 16S rRNA gene sequence is selected from the group consisting of SEQ ID NOs: 1, 14, 15, 16, 17 and 18.
25 . The method of claim 20 , wherein the bacterial strain is of Megasphaera massiliensis.
26 . The method of claim 20 , wherein the bacterial strain is a Megasphaera massiliensis strain deposited under accession number NCIMB 42787.
27 . The method of claim 20 , wherein the bacterial strain selectively inhibits Class I HDAC activity.
28 . The method of claim 27 , wherein the bacterial strain selectively inhibits HDAC1, HDAC2 or HDAC3.
29 . The method of claim 20 , wherein the subject in need thereof has an elevated HDAC activity.
30 . The method of claim 20 , wherein the bacterial strain is administered orally.
31 . The method of claim 20 , wherein the disease or condition is an autoimmune or inflammatory disorder or cancer.
32 . The method of claim 20 , wherein the disease or condition is asthma, arthritis, psoriasis, diabetes, allograft rejection, graft-versus-host disease, an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, or prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer or gastric cancer.
33 . The method of claim 20 , wherein the bacterial strain is dried.
34 . The method of claim 20 , wherein the bacterial strain is comprised in a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier, or diluent.
35 . The method of claim 34 , wherein the pharmaceutical composition comprises at least 1×10 6 CFU/g, with respect to the weight of the composition.
36 . The method of claim 34 , wherein the pharmaceutical composition comprises from 1×10 6 to 1×10 11 CFU/g, with respect to the weight of the composition.
37 . The method of claim 36 , wherein the pharmaceutical composition is encapsulated.
38 . The method of claim 20 , wherein the administering comprises oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.